Table 1:
Participant demographics and clinical characteristics by age group at baseline.
| Variable | Age <18 (N=52) | Age >=18 (N=44) | All (N=96) | |
|---|---|---|---|---|
| Sex, n (%) | Female | 26 (50%) | 17 (39%) | 43 (45%) |
| Male | 26 (50%) | 27 (61%) | 53 (55%) | |
| Enrollment Age, mean (SD) | 11.6 (3.6) | 29.5 (10.0) | 19.8 (11.5) | |
| Enrollment Age, n (%) | 6–11 | 29 (56%) | -- | 29 (30%) |
| 12–17 | 23 (44%) | -- | 23 (24%) | |
| 18–29 | -- | 26 (59%) | 26 (27%) | |
| 30+ | -- | 18 (41%) | 18 (19%) | |
| Genotype Class of the second allele, n (%) | Class I | 4 (8%) | 4 (9%) | 8 (8%) |
| Class II | 44 (85%) | 28 (64%) | 72 (75%) | |
| Class III | 1 (2%) | 1 (2%) | 2 (2%) | |
| Class IV | -- | 1 (2%) | 1 (1%) | |
| Class V | 2 (4%) | 3 (7%) | 5 (5%) | |
| Unknown | 1 (2%) | 7 (16%) | 8 (8%) | |
| Race, n (%) | Black/African-American | 1 (2%) | 2 (5%) | 3 (3%) |
| White | 51 (98%) | 42 (95%) | 93 (97%) | |
| FEV1 % Predicted, mean (SD) | 94.7 (19.3) | 67.0 (22.7) | 82.0 (25.0) | |
| FVC % Predicted, mean (SD) | 99.8 (16.5) | 81.8 (17.1) | 91.6 (19.0) | |
| BMI kg/m2, mean (SD) | 17.9 (2.7) | 23.4 (4.6) | 20.4 (4.6) |